Kanger International Bhd, an investment holding company, engages in the research, development, manufacture, and trade of bamboo flooring and related products in the People's Republic of China. It operates the business across North America, Europe, and Asia. By second halve of the year 2020, Kanger started to explore a plan for a new venture in business: to distribute the Covid-19 vaccines manufactured by Sinopharm in Malaysia. Kanger has tried hard to secure this Covid-19 vaccines business as this new business expected to bring a better results for the company.
THE CURRENT DEVELOPMENT OF KANGER'S BAMBOO BUSINESS
Kanger (017) is a "green" building materials provider, specialising in the manufacturing and trading of bamboo flooring and related products for the residential and commercial markets under its brands 'Kanger' and 'KAR Masterpiece' as well as OEM at the request of its customers. In additional, it also sell strand woven bamboo planks, a semi-finished product from its strand woven bamboo flooring manufacturing process, to furniture and building materials manufacturers as raw materials for their production. The bamboo flooring and related products business is still running well as can be seen at these websites:
On September 2020, Kanger planned to strengthen their bamboo products business. Kanger is on target to become the world’s largest producer of bamboo products with the commencement of a new high-tech bamboo processing plant and R&D centre, which was developed in collaboration with the local government of Jingzhou, Hunan Province, China. Kanger has accumulated vast experience and strong know-how of the bamboo industry, having been involved in the bamboo processing business over the past 16 years.
EFFORTS BY THE COMPANY TO SECURE COVID-19 VACCINE BUSINESS
There are some efforts taken by Kanger to make sure they will successfully enter the Covid-19 distribution business. The chronological list (by date) of the efforts taken are listed below:
1. The Covid-10 vaccine started, when Kanger had entered into a proxy agreement with Shenzhen Public Health Technology Co, Ltd (SZPHT) to procure dealership status from China National Biotec Group Company Ltd (CNBG), which is a subsidiary of China National Pharmaceutical Group Corp (Sinopharm) and distributing it in Southeast Asia.
(Remarks: This agreement has been lapsed because it is only valid until October 8, 2020)
2. Kanger had entered a collaboration agreement with China-based Sinopharm Group Hunan Changde Medical Co Ltd (Sinopharm Group) for the distribution of Covid-19 vaccines developed by China National Biotech Group Company (CNBG) in Malaysia.
3. Kanger revealed their final phase of discussion to be a distributor of Covid-19 vaccines for private sector in Malaysia.
4. Kanger International Bhd has received the nod from the National Institutes of Biotechnology Malaysia (NIBM) to distribute Covid-19 vaccines and medical equipment in Malaysia.
5. Kanger International Bhd will receive 10,000 doses of a Covid-19 vaccine developed by state-owned China National Pharmaceutical Group Corp (Sinopharm) for trial purposes.
(Remarks: The first batch of vaccines is expected to arrive in Malaysia on May 2021).
6. Kanger Donates RM200,000 To Sabah In Efforts To Combat Covid-19
(Remarks: Is it a type of lobby? )
7. Kanger International offers 5,000 doses of Sinopharm Covid-19 vaccine to Sabah
(Remarks: Is it another type of lobby? )
8. MOU with Sabah State Government to obtain Sinopharm Covid-19 vaccines
(Remarks: Will the MOU with Sabah State Government helps the company to obtain approval for Sinopharm Covid-19 vaccine from the government through the National Pharmaceutical Regulatory Agency Negara (NPRA)? )
WHAT IS THE EXPECTED RESULTS?
Based on these reports:
Report 1: The Sinopharm Covid-19 vaccine is in the process of being approved in Malaysia, including by the National Pharmaceutical Regulatory Agency (NPRA).
“We will ensure that we obtain the required approvals from relevant authorities before we commence distribution of the Sinopharm vaccines.
“Once approvals are obtained, the people of Sabah will be one of the early recipients of the Sinopharm vaccines,” Kuah said.
Report 2: Covid-19: Those who want to bring in Sinopharm vaccine can register it with NPRA, says Khairy.
Report 3: Supplies through Putrajaya is just one of the options available, and that state governments could source their own as long as they are approved by the National Pharmaceutical Regulatory Agency (NPRA) – says Khairy
Report 4: PM says anyone can buy Covid-19 vaccines, as long as approved by NPRA.
Therefore, we are hoping that, sooner Kanger will be successful in securing their objective to be an approved Covid-19 vaccines distributor in Malaysia.
* DISCLAIMER: All the information given is not for buy call or sell call purposes.